IP Management/Tech Transfer Strategies for Improved Global Health

Prof. Patrick Nef, PhD, Chief Business Officer
Sylvie Fonteilles-Drabek, Senior Legal Officer

BIO International Convention, 18-21 May 2009, Atlanta

Curing Malaria Together
www.mmv.org

Medicines for Malaria Venture
Contents

- MMV created to address malaria burden
- MMV’s public-private partnership model
  - Partners
  - Donors
  - Portfolio
  - Incentives for R&D
- MMV’s IP management tailored to partner needs
- MMV’s partnership model a success
MMV: founded in the late 1990’s
MMV’s Mission

- Discover
- Develop
- Deliver

Medicines

- Treating
- Preventing
- Eradicating (new)

Malaria
MMV >100 partners across the world
10 years work
1,000 man years

The largest malaria R&D portfolio
Proven Concept
Contents

• MMV created to address malaria burden
• MMV’s public-private partnership model
  • Partners
  • Donors
  • Portfolio
  • Incentives for R&D
• MMV’s IP management tailored to partner needs
• MMV’s partnership model a success
Rights to Program (Foreground) IP

**Background**
- Patentable data are generated by research collaborations managed and funded by MMV
- IP rights initially vest in the Partners
- Filing and maintenance costs are borne by Partners
- MMV need an exclusive license to Program IP to pursue the development of anti-malarial drugs

**Problem**
- Partners want MMV to pay for patent costs

**Solution**
- MMV restricts its rights only to the Field of malaria in endemic regions
- Partners retain IP rights for all other indications
Rights to pre-existent (Background) IP

- **Background**
  - Rights to pre-existent IP is necessary for moving forward with the new research collaboration program
  - Partner grant MMV a non-exclusive license to Background IP to exploit Foreground IP

- **Problem**
  - Partner may not license rights to patented background IP

- **Solution**
  - MMV agrees with Partner to restricts its rights to background IP only necessary to exploit foreground IP and only for a limited time period
IP Rights - Example 3

• **Screening Program IP**

• **Background**
  - Partner’s compounds are screened using MMV’s screening centers and assays

• **Problem**
  - To whom new Program IP belong?
    - Partner?
    - MMV?
    - Compound provider?

• **Solution**
  - Program IP relating to the compound activities belong to Partner or compound provider, not MMV
  - Program IP relating to assay development belongs to inventor
Contents

- MMV created to address malaria burden
- MMV’s public-private partnership model
  - Partners
  - Donors
  - Portfolio
  - Incentives for R&D
- MMV’s IP management tailored to partner needs
- MMV’s partnership model is a success
Novartis - MMV Partnership started Nov 2003

- "This partnership with MMV signals our commitment to the global fight against malaria," said Dr. Daniel Vasella, Chairman and CEO of Novartis. "We believe the most promising way to help increase access to life-saving therapies to the poorest people in the world is by working with partners such as MMV and the WHO with whom we already cooperate in the fight against malaria and leprosy."
Coartem D: SwissMedic Approval in 2009

- Fixed Dose Combination ACT
- WHO Treatment Guidelines
- WHO Prequalified
- WHO Essential Medicines List
- Approved by SRA (Swissmedic)
- Global Fund Approved List
- Multilingual Educational Materials and Support
- Safety Legacy > 200m treatments
- Child Friendly Pediatric Formulation
- Affordable
Coartem Dispersible – IP

• Background IP and Foreground IP belongs to the party which created it

• Novartis has the exclusive right to manufacture, let manufacture, sell, let sell, commercialize, let commercialize, distribute and let distribute the product

• Novartis to diligently distribute the product for use in the field of Malaria in malaria endemic countries

• If withdrawing, Novartis to make its Background and Foreground IP available to a third party for the distribution of the product for use in the field of malaria